Key Highlights

  • USD 4.00 is the price of eXoZymes (NASDAQ:EXOZ), down 13.04% on 24,360 shares, with a market capitalization of USD 37.13 million, per published market data (October 16, 2026 premarket). That is 55.5% below USD 8.99, own arithmetic on two published prices.
  • USD 8.99 per share and USD 0.02 per warrant was the June 2026 offering price. The company closed 330,575 units on June 17, 2026 for gross proceeds of USD 5.95 million, own arithmetic, each unit holding two shares and one warrant.
  • USD 0.001 is the warrant exercise price if eXoZymes (NASDAQ:EXOZ) sells equity below USD 8.99 before June 5, 2027. Qualifying original purchasers receive the reset, while the standard exercise price is USD 11.24, per the June 2026 offering terms.
  • October 9, 2026 is the date eXoZymes (NASDAQ:EXOZ) filed an 8-K furnishing an investor presentation dated October 6, 2026. The filing states it may be shown to bankers and offering participants, and it does not announce an offering, price or size.

Price Action and Liquidity Review

The stock fell 13.04% to USD 4.00 from an implied prior close of USD 4.60, own arithmetic. Volume of 24,360 shares ran at 3.13 times relative volume, which implies average volume of 7,783 shares, own arithmetic. Turnover was USD 97,440, price times volume, equal to 0.26% of market capitalization, own arithmetic. The market capitalization implies 9.28 million shares. No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026.

Capital Structure and Dilution

The company directed June proceeds to its NCT nutraceutical ingredient, other products, research and working capital. MDB Capital was sole book-runner on the offering, made from a shelf effective January 23, 2026; shelf capacity is not disclosed in the filing reviewed. A further placement closed June 30, 2026: 35,555 units at USD 18.00 for gross proceeds of USD 639,990. Cash of USD 5.65 million was reported with the August 20, 2026 update, a figure not matched to a filing reviewed. Against a trailing loss implied by EPS of negative USD 1.20 and 9.28 million shares, that cash covers 6.1 months, an estimate, own arithmetic.

Warrant Reset and Monitoring Points

The June warrants are exercisable from June 5, 2027 at USD 11.24 and expire June 5, 2031. If the company sells shares or convertible securities below USD 8.99 before June 5, 2027, the price falls to USD 0.001 for qualifying holders. At USD 4.00, any new offering prices below that trigger, so 330,575 warrants could convert into shares at a cost of USD 331, own arithmetic, worth USD 1.32 million at the current price, or 3.6% of market capitalization. The third quarter report date was not disclosed in filings reviewed.

Where Things Stand

The gap reflects a market discounting a company that needs capital: eXoZymes (NASDAQ:EXOZ) sold stock at USD 8.99 in June, and published market data now shows USD 4.00, with no identified catalyst for the latest 13.04% fall. The evidence balance points to a financing overhang, since the warrant reset raises the cost of any new equity. Cash of USD 5.65 million is not matched to a filing reviewed, and no Nasdaq bid deficiency was identified. Watch for an offering announcement, any further 8-K and the third quarter report.